After an aggressive acquisition policy, why did you decide to sell?
We strongly felt it was the right time to put the company in a new orbit and a much higher, sustainable growth trajectory. It was necessary to transform the business, create a new business model that combines strengths of a big pharma company and a generics company.
Some analysts are concerned....
Post the deal, I've been flooded with messages from external audiences, applauding it and saying it's a game- changer. I believe the deal is extremely positive for all stakeholders. The market capitalisation of the company goes up and a cash infusion of approximately $1 billion will help retire debt and aggressively explore growth options.
Why do you believe more companies will try and emulate Ranbaxy's way?
This model offers tremendous growth opportunities. Daiichi Sankyo is a strong innovator and we have strengths in generics. The coming together will create a powerful pan-global presence.
What can drug consumers and Ranbaxy...